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Abstract
The hippocampus plays key roles in learning and memory and is a main target of 
Alzheimer’s disease (AD), which causes progressive memory impairments. Despite 
numerous investigations about the processes required for the normal hippocampal 
functions, the neurotransmitter receptors involved in the synaptic deficits by which 
AD disables the hippocampus are not yet characterized. By combining histoblots, 
western blots, immunohistochemistry and high-resolution immunoelectron microscopic 
methods for GABAB receptors, this study provides a quantitative description of the 
expression and the subcellular localization of GABAB1 in the hippocampus in a 
mouse model of AD at 1, 6 and 12  months of age. Western blots and histoblots 
showed that the total amount of protein and the laminar expression pattern of 
GABAB1 were similar in APP/PS1 mice and in age-matched wild-type mice. In con-
trast, immunoelectron microscopic techniques showed that the subcellular localization 
of GABAB1 subunit did not change significantly in APP/PS1 mice at 1  month of 
age, was significantly reduced in the stratum lacunosum-moleculare of  CA1 pyramidal 
cells at 6  months of age and significantly reduced at the membrane surface of CA1 
pyramidal cells at 12  months of age. This reduction of plasma membrane GABAB1 
was paralleled by a significant increase of the subunit at the intracellular sites. We 
further observed a decrease of membrane-targeted GABAB receptors in axon ter-
minals contacting CA1 pyramidal cells. Our data demonstrate compartment- and 
age-dependent reduction of plasma membrane-targeted GABAB receptors in the CA1 
region of the hippocampus, suggesting that this decrease might be enough to alter 
the GABAB-mediated synaptic transmission taking place in AD.
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neurodegen-
erative disease in the elderly population. Alzheimer’s disease 
progression has been associated with a gradual damage in 
function and structure of the hippocampus, a vulnerable 
brain region involved in the memory formation and in the 
cognition. In particular, the CA1 hippocampal region is 
one of the most affected brain areas in AD, suffering a 
variety of neuronal alterations, including dendritic changes 
in pyramidal cells and pronounced loss of neurons (55, 56). 
The three major neuropathology hallmarks of AD are extra-
cellular amyloid plaques containing amyloid β (Aβ) peptides 
derived from amyloid precursor protein (APP), neurofibrillary 
tangles of aggregated hyperphosphorylated tau in neurons 
and synapse loss (5). The progressive increase in synapse 
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loss correlates with cognitive decline and is proposed to 
underlie learning and memory deficits in AD (21).
Amyloid β (Aβ) has been implicated in the pathogenesis 
of AD by creating a microenvironment that damages the 
dendritic spines, which represent the major postsynaptic ele-
ments of excitatory synapses in the cerebral cortex (16), 
and are fundamental to memory formation, learning and 
cognition (30). Growing evidence supports that structural 
plasticity impairments on excitatory synapses are linked to 
a gross disruption of the glutamatergic system (36, 41, 55, 
58, 59). Thus, N-methyl-D-aspartate (NMDA) receptors acti-
vation and removal of AMPA receptors have been implicated 
in AD-related synaptic dysfunctions (20, 59). The neuro-
transmitter γ-aminobutyric acid (GABA) acts through GABAA 
and GABAB receptors to inhibit neurons  (3, 13). While 
alterations in the expression of GABAA receptor subunits 
in the AD hippocampus differ (28) alterations in GABAB 
receptor expression are less well understood and only recently 
it has been shown a direct molecular and functional link 
between APP and GABAB receptors (9, 45, 47).
GABAB receptors have modulatory actions on neuronal 
excitability and neurotransmitter release, and are involved in 
a number of physiological and pathophysiological processes 
(3), including AD. Two subunits, GABAB1 and GABAB2, are 
required to form functional receptors (26, 37). 
Autoradiographic, in situ hybridisation and immunohistochemi-
cal studies showed that the hippocampus expresses a high-
density of GABAB receptors  (4, 6, 7, 12, 25, 32). 
Immunoelectron microscopic studies demonstrated an associa-
tion of GABAB receptors with postsynaptic and presynaptic 
sites at excitatory synapses in the hippocampus, with a par-
ticularly high abundance in the dendritic spines of pyramidal 
cells (8, 27, 32, 53). Since dendritic spines and excitatory 
synapses are lost in AD it is expected that both the distribu-
tion and functions of GABAB receptors are affected. However, 
it remains unclear how these receptors reorganize at the surface 
of hippocampal neurons in AD brains. For this purpose, our 
work adopted transgenic mice overexpressing mutant familial 
AD genes [amyloid-β protein precursor (AβPP), presenilin-1 
(PS1)-dE9], considered one of the most relevant animal models 
of AD. These animals show Aβ deposition by 4  months with 
a progressive increase in senile plaque number up to 12 months 
and cognitive impairments (14, 15).
To identify possible alterations in the expression and 
subcellular localization of GABAB receptors in the APP/
PS1 mice we used western blots, histoblots and high-resolution 
immunohistochemical techniques in combination with quan-
titative approaches at different ages. Here we provide evidence 
for a significant reduction in the plasma membrane expres-
sion of GABAB receptors in CA1 pyramidal cells in the 
APP/PS1 AD mouse model.
MATERIAL AND METHODS
Animals
The mouse line used for this study (APP/PS1; hemizygote 
animals) expressed Mo/Hu APP695swe construct in conjunc-
tion with the exon 9-deleted variant of human presenilin 1 
(PS1-dE9) (46). Control mice were age-matched littermates 
without the transgene (wild type). Mice of all genotypes 
were aged to 1, 6 and 12  months before use in a battery 
of biochemical and morphological experiments. For each 
age and genotype, four mice were used for western blot, 
four mice were used for histoblot techniques, four mice 
were used for SDS-FRL techniques and three mice were 
used for pre-embedding immunoelectron microscopic analyses. 
All mice were obtained from the Animal House Facility of 
the University of Castilla-La Mancha (Albacete, Spain). 
Animals were housed in cages of 2 or more mice, main-
tained on a 12  hour light/12  hour dark cycle at 24°C and 
received food and water ad libitum. Care and handling of 
animals prior to and during experimental procedures were 
in accordance with Spanish (RD 1201/2015) and European 
Union regulations (86/609/EC), and the protocols were 
approved by the local Animal Care and Use Committee.
For western blots, the animals were deeply anesthetized 
by intraperitoneal injection of ketamine/xylazine 1:1 (0.1 
mL/kg b.w.), the hippocampus was extracted, frozen rapidly 
in liquid nitrogen and stored at −80°C. For histoblotting, 
the animals were deeply anesthetized by intraperitoneal injec-
tion of ketamine/xylazine 1:1 (0.1  mL/kg b.w.), the brains 
were quickly frozen in liquid nitrogen and stored at −80°C. 
For immunohistochemistry at the light and electron micro-
scopic levels, animals were deeply anesthetized by intraperi-
toneal injection of ketamine-xylazine 1:1 (0.1  mL/kg) and 
transcardially perfused with ice-cold fixative containing: (i) 
2% paraformaldehyde in 0.1  M phosphate buffer (PB, pH 
7.4) for 12 min (for SDS-FRL technique), or (ii) 4% para-
formaldehyde, 0.05% glutaraldehyde and 15% (v/v) saturated 
picric acid made up in 0.1  M phosphate buffer (PB), pH 
7.4 (for light microscopy and pre-embedding immunogold 
techniques). After perfusion, brains were removed and 
immersed in the same fixative for 2  h or overnight at 4°C. 
Tissue blocks were washed thoroughly in 0.1 M PB. Coronal 
sections (60  µm thickness) were cut on a Vibratome (Leica 
V1000).
Antibodies and chemicals
An affinity-purified polyclonal antibody against GABAB1 
(B17, aa. 901-960 of rat GABAB1) was raised in rabbit, 
and used for immunohistochemical techniques at the light 
and electron microscopic levels. The characteristics and 
specificity of the anti-GABAB1 antibody have been described 
elsewhere (26, 35, 53). For western blots and histoblots, a 
mouse monoclonal anti-GABAB1 (sc-166408; D-2, aa 929-
958 of rat C-terminus of GABAB1) antibody was used (Santa 
Cruz, CA, USA), and we provided additional information 
on its specificity. A monoclonal anti-α-Tubulin (DM1A; ref 
CP06) was obtained from Millipore (Millipore Corporation, 
Burlington, MA, USA). An affinity-purified polyclonal anti-
body against β-amyloid (ref  #2454, detecting human Aβ-40 
and Aβ-42 peptides) raised in rabbit was obtained from 
Cell Signalling Technology (Leiden, The Netherlands).
The secondary antibodies used were as follows: goat anti-
mouse IgG-horseradish peroxidase (1:2000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), goat anti-rabbit 
IgG-horseradish peroxidase (1:15  000; Pierce, Rockford, 
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USA), alkaline phosphatase AP-goat anti-mouse IgG 
(H  +  L) and AP-goat anti-rabbit IgG (H  +  L) (1:5000; 
Invitrogen, Paisley, UK), goat anti-rabbit IgG coupled to 
1.4  nm gold (1:100; Nanoprobes Inc., Stony Brook, NY, 
USA) and anti-rabbit IgG conjugated to 10  nm gold par-
ticles (1:100; British Biocell International, Cardiff, UK).
Western blots
Hippocampi were homogenized in 50  mM Tris Base, pH 
7.4 and Protease Inhibitor Cocktail (Thermo Scientific, 
Pierce, Rockford, USA) with a pestle motor (Sigma-
Aldrich). The homogenized tissue was centrifuged 10  min 
at 1000  ×  g at 4°C and the supernatant was centrifuged 
30  min at 12000  ×  g (Centrifuge 5415R, Eppendorf, 
Hamburg, Germany) at 4°C, the pellet containing the 
membrane extracts were resuspended in 50  mM Tris Base, 
pH 7.4 and Protease Inhibitor Cocktail (Thermo Scientific, 
Pierce, Rockford, USA). The protein content of  each 
membrane extract was determined by BCA Protein Assay 
Kit (Thermo Scientific). Twenty-five micrograms of  mem-
brane protein were loaded in Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS/PAGE) using 7.5% 
polyacrylamide with loading sample buffer (0,05  M Tris 
pH 6.8, 2% SDS, 10% glycerol, 0,05% β-mercaptoethanol 
and 0,001% bromophenol blue). The proteins were trans-
ferred to PVDF membranes using a semidry transfer system 
and immunoblotted with anti-GABAB1 (1:500) and anti-
α-Tubulin (1:1000). Protein bands were visualized after 
application of  a mouse IgG kappa-binding protein coupled 
to horseradish peroxidase (1:1000) using the enhanced 
chemiluminescence (ECL) blotting detection kit 
(SuperSignal West Dura Extended Duration Substrate, 
Pierce, Rockford, USA). Blots were captured and quanti-
fied by densitometry using a LAS4000 MINI (Fujifilm, 
Japan). A series of  primary and secondary antibody dilu-
tions and incubation times were used to optimize the 
experimental conditions for the linear sensitivity range, 
confirming that our labeling was well below the saturation 
levels.
Histoblotting
The regional distribution of GABAB1 was analysed in rodent 
brains, using an in situ blotting technique (histoblot) (1, 
52). Briefly, horizontal cryostat sections (10 µm) from mouse 
brain were apposed to nitrocellulose membranes moistened 
with 48  mM Tris-base, 39  mM glycine, 2% (w/v) sodium 
dodecyl sulphate and 20% (v/v) methanol for 15  min at 
room temperature (~20°C). After blocking in 5% (w/v) nonfat 
dry milk in phosphate-buffered saline, nitrocellulose mem-
branes were treated with DNAse I (5 U/mL), washed and 
incubated in 2% (w⁄v) sodium dodecyl sulphate and 100 mm 
β-mercaptoethanol in 100 mM Tris–HCl (pH 7.0) for 60 min 
at 45°C to remove adhering tissue residues. After extensive 
washing, the blots were reacted with affinity-purified anti-
GABAB1 antibodies (0.5  mg⁄mL) in blocking solution over-
night at 4°C. The bound primary antibodies were detected 
with alkaline phosphatase-conjugated anti-rabbit IgG second-
ary antibodies (52). A series of primary and secondary 
antibody dilutions and incubation times were used to optimize 
the experimental conditions for the linear sensitivity range 
of the alkaline phosphatase reactions. To compare the expres-
sion levels of GABAB1 between the two genotypes (wild 
type and APP/PS1) and ages (1, 6 and 12-months), all 
nitrocellulose membranes were processed in parallel, and 
the same incubation time for each reagent was used for 
the antibody.
To facilitate the identification of  brain regions, structures 
and cell layers, adjacent cryostat sections were stained 
with cresyl violet for the two genotypes (wild type and 
APP/PS1) and ages (1, 6 and 12-months; not shown). 
Digital images were acquired by scanning the nitrocellulose 
membranes using a desktop scanner (HP Scanjet 8300). 
Image analysis and processing were performed using the 
Adobe Photoshop software (Adobe Systems, San Jose, CA, 
USA) as described previously (10). All of  the images were 
processed with the same equipment in the same way to 
allow comparison of  the intensity of  grayscale images 
between experimental groups and in different brain regions. 
The pixel density (arbitrary units) of  immunoreactivity 
was measured using open circular cursors with a diameter 
of  0.10  mm. The cursors were placed in different brain 
regions identified based on the adjacent cresyl violet-stained 
sections (10). We used background correction to eliminate 
the potential differences in optical densities across differ-
ent sections in different experiments. The average of  eight 
background determinations carried out near the brain 
protein-containing areas of  the immunostained nitrocel-
lulose membranes was subtracted from the average pixel 
densities measured within the brain regions. Following 
background corrections, the average pixel density for the 
whole region from one animal counted as one ‘n’. Under 
these conditions, labeling performed on different days 
produced very consistent results. Data were analyzed and 
plotted using the software Analysis (GraphPad Prism, San 
Diego, USA).
Immunohistochemistry for light microscopy
Immunohistochemical reactions at the light microscopic level 
were carried out using the immunoperoxidase method as 
described earlier (34). Briefly, sections were incubated in 
10% normal goat serum (NGS) diluted in 50  mM Tris 
buffer (pH 7.4) containing 0.9% NaCl (TBS), with 0.2% 
Triton X-100, for 1  h. Sections were incubated in anti-
GABAB1 (1–2  µg/mL diluted in TBS containing 1% NGS) 
or in anti-β amyloid (1–2  µg/mL diluted in TBS containing 
1% NGS), followed by incubation in biotinylated goat anti-
rabbit IgG (Vector Laboratories, Burlingame, CA) diluted 
1:200 in TBS containing 1% NGS. Sections were then trans-
ferred into avidin–biotin–peroxidase complex (ABC kit, 
Vector Laboratories). Bound peroxidase enzyme activity was 
revealed using 3,3′-diaminobenzidine tetrahydrochloride 
(DAB; 0.05% in TB, pH 7.4) as the chromogen and 0.01% 
H2O2 as the substrate. Finally, sections were air-dried and 
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mounted prior to observation in a Leica photomicroscope 
(DM2000) equipped with differential interference contrast 
optics and a digital imaging camera.
Immunohistochemistry for electron microscopy
Immunohistochemical reactions at the electron microscopic 
level were carried out using the pre-embedding immunogold 
and the SDS-digested freeze-fracture replica labeling 
(SDS-FRL) methods as described earlier (33, 34, 50).
Pre-embedding immunogold method. Briefly, free-floating 
sections obtained from the two genotypes (WT and APP/PS1) 
and three ages (1, 6 and 12-months) were incubated in 
parallel in 10% (v/v) NGS diluted in TBS. Sections were 
then incubated in anti-GABAB1 antibodies (3-5 μg⁄mL diluted 
in TBS containing 1% (v/v) NGS), followed by incubation 
in goat anti-rabbit IgG coupled to 1.4 nm gold (Nanoprobes 
Inc., Stony Brook, NY, USA), respectively. Sections were 
postfixed in 1% (v/v) glutaraldehyde and washed in double-
distilled water, followed by silver enhancement of the gold 
particles with an HQ Silver kit (Nanoprobes Inc.). Sections 
were then treated with osmium tetraoxide (1% in 0.1  M 
phosphate buffer), block-stained with uranyl acetate, dehy-
drated in graded series of ethanol and flat-embedded on 
glass slides in Durcupan (Fluka) resin. Regions of interest 
were cut at 70–90  nm on an ultramicrotome (Reichert 
Ultracut E, Leica, Austria) and collected on single slot 
pioloform-coated copper grids. Staining was performed on 
drops of 1% aqueous uranyl acetate followed by Reynolds’s 
lead citrate. Ultrastructural analyses were performed in a 
JEOL-1010 electron microscope.
SDS-FRL technique. Animals were anesthetized with 
sodium pentobarbital (50  mg/kg, i.p.) and perfused tran-
scardially with 25 mM PBS for 1 min, followed by perfusion 
with 2% paraformaldehyde in 0.1  M phosphate buffer (PB) 
for 12  min. The hippocampi were dissected and cut into 
sagittal slices (130  µm) using a Microslicer (Dosaka, Kyoto, 
Japan) in 0.1  M  PB. Next, we trimmed hippocampal slices 
containing the CA region and immersed them in graded 
glycerol of 10%–30% in 0.1  M  PB at 4°C overnight. Slices 
were frozen using a high-pressure freezing machine (HPM010, 
BAL-TEC, Balzers). Slices were then fractured into two 
parts at -120°C and replicated by carbon deposition (5  nm 
thick), platinum (60° unidirectional from horizontal level, 
2  nm) and carbon (15-20  nm) in a freeze-fracture replica 
machine (BAF060, BAL-TEC, Balzers). Replicas were trans-
ferred to 2.5% SDS and 20% sucrose in 15  mM Tris buffer 
(pH 8.3) for 18  h at 80°C with shaking to dissolve tissue 
debris. The replicas were washed three times in 50  mM 
Tris-buffered saline (TBS, pH 7.4), containing 0.05% bovine 
serum albumin (BSA) and then blocked with 5% BSA in 
the washing buffer for 1  h at room temperature. Next, the 
replicas were washed and reacted with a polyclonal rabbit 
antibody for GABAB1 (5μg/mL) at 15°C overnight. Following 
three washes in 0.05% BSA in TBS and blocking in 5% 
BSA/TBS, replicas were incubated in secondary antibodies 
conjugated with 10  nm gold particles overnight at room 
temperature. When the primary antibody was omitted, no 
immunoreactivity was observed. After immunogold labeling, 
the replicas were immediately rinsed three times with 0.05% 
BSA in TBS, washed twice with distilled water and picked 
up onto grids coated with pioloform (Agar Scientific, Stansted, 
Essex, UK).
Quantification and analysis of SDS-FRL data
The labeled replicas were examined using a transmission 
electron microscope (JEOL-1010) and photographed at 
magnifications of  60,000, 80,000 and 100,000. All antibod-
ies used in this study were visualized by immunoparticles 
on the protoplasmic face (P-face), consistent with the 
intracellular location of  their epitopes. Nonspecific back-
ground labeling was measured on E-face surfaces in wild-
type mice. Digitised images were then modified for 
brightness and contrast using Adobe PhotoShop CS5 
(Mountain View, CA, USA) to optimize them for quan-
titative analysis. The quantitative analyses were done using 
the software GPDQ (Gold Particle Detection and 
Quantification) developed recently to perform automated 
and semiautomated detection of  gold particles present in 
a given compartment of  neurons (33).
Density gradient of GABAB1 along the membrane surface. 
The procedure was similar to that used previously (33). 
Briefly, immunogold labeling for GABAB1 was achieved 
from replicas containing all layers of  the CA1 region, so 
that the laminar distribution could be compared under 
identical conditions for each animal and experimental 
group. Quantitative analysis of  immunogold labeling for 
GABAB1 was performed on ten different dendritic com-
partments of  pyramidal cells in all dendritic layers of  the 
CA1 region and in somata of  pyramidal cells in the stra-
tum pyramidale. The dendritic compartments analysed were 
the main dendritic shaft (apical dendrites), spiny branchlets 
(oblique dendrites) and dendritic spines. Oblique dendrites 
were identified based on their small diameter and the 
presence of  at least one emerging spine from the dendritic 
shaft. Dendritic spines were considered as such if: (i) they 
emerged from a dendritic shaft or (ii) they opposed an 
axon terminal. Axon terminals were identified based on: 
(i) the concave shape of  the P-face and the accumulation 
of  intramembrane particles (IMPs) on the opposing exo-
plasmic-face (E-face) of  a spine or dendrite; or (ii) the 
presence of  synaptic vesicles on their cross-fractured por-
tions. Non-specific background labeling was measured on 
E-face structures surrounding the measured P-faces. Images 
of  the identified compartments were selected randomly 
over the entire dendritic tree of  CA1 pyramidal cells and 
then captured with an ORIUS SC1000 CCD camera (Gatan, 
Munich, Germany). The area of  the selected profiles and 
the number of  immunoparticles were measured using our 
GPDQ software (33). Immunoparticle densities were pre-
sented as mean  ±  SEM between animals. Statistical com-
parisons were performed with GraphPad Prism 5 software 
(La Jolla, CA, USA).
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Number of GABAB1 immunoparticles in clusters along 
the membrane surface
To determine the number of GABAB1 immunoparticles com-
posing the clusters that are present in different compartments 
of CA1 pyramidal cells in the two genotypes (wild type 
and APP/PS1) and the three ages (1, 6 and 12-months), 
we used the same set of images for the above analysis and 
the GPDQ software. The software reports the number of 
particles, their area (as the area inside the convex hull of 
the particles in the cluster) or the distance to the nearest 
cluster of particles. By default, the software uses the mini-
mum number of particles in a cluster fixed to three, so all 
clusters with one or two particles are discarded. More infor-
mation in all parameters that need to be set in the software 
is detailed elsewhere (33). The data were expressed as the 
percentage of clusters with distinct number of immunopar-
ticles per cluster, in different compartments both in wild-type 
and APP/PS1 mice.
Quantification and analysis of pre-embedding 
immunogold data
To establish the relative abundance of  GABAB1 immuno-
reactivity in different compartments of  CA1 pyramidal 
cells between the two genotypes (wild type and APP/PS1) 
and the three ages (1, 6 and 12-months), we used 60-μm-thick 
coronal slices processed for pre-embedding immunogold 
immunohistochemistry. The procedure was similar to that 
used previously (34). Briefly, for each of  three adult ani-
mals, three samples of  tissue were obtained for the prepa-
ration of  embedding blocks, thus using in total nine blocks. 
To minimize false negatives, electron microscopic serial 
ultrathin sections were cut close to the surface of  each 
block, as immunoreactivity decreased with depth. We esti-
mated the quality of  immunolabeling by always selecting 
the areas with optimal gold labeling at approximately the 
same distance from the cutting surface. Randomly selected 
areas were then photographed from the selected ultrathin 
sections and used with final magnification between 30  000 
and 50  000×. Quantification of  immunogold labeling was 
carried out in reference areas of  the CA1 region totaling 
approximately 2500 µm2. We counted immunoparticles 
identified in each reference area and present in different 
subcellular compartments: dendritic spines, dendritic shafts 
and axon terminals. The data were expressed as a percent-
age of  immunoparticles in each subcellular compartment, 
both in the plasma membrane and at intracellular sites.
Controls
To test method specificity in the procedures for electron 
microscopy, the primary antibody was either omitted or 
replaced with 5% (v/v) normal serum of the species of the 
primary antibody, resulting in total loss of the signal. For 
the pre-embedding technique, labelling patterns were also 
compared with those obtained with Calbindin (polyclonal 
rabbit anti-Calbindin D-9k CB9; Swant, Marly, Switzerland); 
only the antibodies against GABAB1 consistently labeled the 
plasma membrane. To test method specificity in the proce-
dures for western blots and histoblots, antisera against GABAB1 
was tested on hippocampal membranes and brain sections, 
respectively, of GABAB1 knockout mice. In our samples, the 
immunolabeling signal was completely absent in the knockout 
mice, while a strong signal was present in wild-type mice.
Data analysis
Statistical analyses for morphological data were performed 
using SigmaStat Pro (Jandel Scientific) and data were pre-
sented as mean ± SEM unless indicated otherwise. Statistical 
significance was defined as P  <  0.05. The statistical evalu-
ation of the immunogold densities was performed using the 
two-way ANOVA test and further compared with the 
Bonferroni post hoc test.
RESULTS
Similar brain expression of GABAB receptors in 
control and APP/PS1 mice
We first determined whether the GABAB receptor expression 
was impaired in the brain of APP/PS1 mice at time points 
when Aβ deposition is observed. We selected ages with (i) 
no sign of pathology (1  month; Figure 1A-C), (ii) starting 
Aβ deposition (6  months; Figure 1D-F) and (iii) cognitive 
deficits, severe synapse loss and widespread Aβ deposition 
(12  months; Figure 1G-I). To analyse region-dependent 
alterations in GABAB receptor expression in the brain of 
APP/PS1 and age-matched wild-type mice, we used a GABAB1 
subunit-specific antibody in conventional histoblots (33).
In the brain, the overall expression of GABAB1 revealed 
marked region-specific differences at all ages  analysed, with 
very similar expression patterns in  wild type and APP/PS1 
mice (Figure 1A-I). In wild-type mice of the three ages ana-
lyzed, immunoreactivity for GABAB1 was widely distributed 
in the brain, with strongest immunoreactivities in the cerebellum 
and thalamus, moderate labeling in the hippocampus, cortex 
and septum and weak labeling in the caudate putamen and 
midbrain nuclei, including the inferior and superior colliculi 
(Figure 1A,D,G). This expression pattern was very similar in 
the brain of APP/PS1 mice at 1 (Figure 1B), 6 (Figure 1E) 
and 12  months (Figure 1H) of age. Quantitative analyses was 
performed to compare the protein densities for 1, 6 and 
12 months of age revealed that GABAB1 expression levels were 
similar between wild-type and APP/PS1 mice (Figure 1C,F,I).
Similar hippocampal expression of GABAB 
receptors in control and APP/PS1 mice
We next focused on the hippocampus, considered as one of 
the most vulnerable brain regions affected in AD (56, 57) 
and explored the laminar expression pattern of GABAB 
receptors. Using the histoblot technique, we observed that 
GABAB1 was widely expressed in all hippocampal subfields 
and dendritic layers at the three ages of wild-type and APP/
PS1 mice (Figure 2A-I). In the CA1 region of wild-type 
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mice, at 1, 6 and 12  months of age, GABAB1 expression 
was moderate to strong, with the strata oriens and radiatum 
showing the lowest and the stratum lacunosum-moleculare 
showing the highest expression levels (Figure 2A,D,G). The 
CA3 region of wild-type mice exhibited higher GABAB1 
expression level than the CA1 region, with the stratum lacu-
nosum-moleculare showing the highest expression level within 
the hippocampus, followed by the stratum radiatum (Figure 
2A,D,G). The stratum lucidum showed weak expression level 
throughout (Figure 2A,D,G). In the dentate gyrus of wild 
type, GABAB1 immunostaining was weak in the hilus and 
moderate in the molecular layer (Figure 2A,D,G). The stratum 
pyramidale of the CA1 and CA3 regions and the granule 
cell layer of the dentate gyrus showed the weakest GABAB1 
expression (Figure 2A,D,G). The expression pattern of wild-
type mice was similar to that of APP/PS1 mice at 1 (Figure 
2B), 6 (Figure 2E) and 12  months (Figure 2H) of age. 
Quantitative analyses of protein densities performed at the 
three ages confirmed that the expression levels of GABAB1 
in all subfields and dendritic layers analysed was unchanged 
between wild-type and APP/PS1 mice (Figure 2C,F,I).
To corroborate the above histoblot data, we further evalu-
ated the expression of GABAB1 in the hippocampus using 
western blot. The mouse pan anti-GABAB1 subunit antibody 
revealed two immunoreactive products with estimated molecu-
lar masses of 130 and 100  kDa (Figure 2J), corresponding 
to the GABAB1a and to the GABAB1b proteins, respectively 
(25). Since GABAB1a and GABAB1b subunits show a dif-
ferential compartmentalization in hippocampal neurons (53), 
both subunits were quantified. The levels of GABAB1a and 
GABAB1b subunit proteins were unchanged in APP/PS1 
compared to age-matched wild-type mice (Figure 2J,K). As 
Figure 1. Regional expression of GABAB1 in the brain in wild-type and 
APP/PS1 mice. A-I. The expression of the GABAB1 protein was visualized 
in histoblots of horizontal brain sections at 1, 6 and 12 months of age in 
wild-type and APP/PS1 mice using an affinity-purified anti-GABAB1 
antibody. GABAB1 expression in different brain regions was determined 
by densitometric analysis of the scanned histoblots (panels C, F and I). 
The strongest GABAB1 expression was detected in the cerebellum (Cb) 
and thalamus (Th), with moderate expression in the hippocampus (Hp), 
cortex (Ctx) and septum (Sp). The weakest expression level was 
detected in the caudate putamen (CPu). Densitometric analysis showed 
no differences in GABAB1 expression in APP/PS1 mice compared to age-
matched wild type controls. Error bars indicate SEM. Scale bars: 0.2 cm. 
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a control, to validate the specificity of the immunoreactions, 
GABAB1 knockout (KO) mice (18) were used. The pattern 
of immunolabeling for GABAB1 observed in the brain of 
wild-type mice using western blots and histoblots was com-
pletely missing in that of the corresponding GABAB1 knockout 
mice (GABAB1 -/- brains) (Figure 2L,M), thus demonstrating 
the specificity of the antibody.
Similar cellular distribution of GABAB receptors 
in control and APP/PS1 mice
Given the similar laminar expression of  GABAB1 in the 
hippocampus at the three ages analysed, we next sought 
to investigate the cellular distribution of  the receptor at 
12  months of  age, using light microscopy immunohisto-
chemical techniques. Both in wild-type and APP/PS1 mice, 
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immunoreactivity for GABAB1 in the CA1 and CA3 regions 
was the highest in the stratum lacunosum-moleculare and 
weaker in the strata oriens and radiatum (Figure 3A-H). 
In the dentate gyrus, immunoreactivity for GABAB1 was 
strongest in the molecular layer and weakest in the hilus 
(Figure 3A-H). In the stratum pyramidale of  the CA1 
and CA3 regions and the granule cell layer of  the dentate 
gyrus immunoreactivity for GABAB1 was weakest in the 
hippocampus, but again very similar between wild-type 
and APP/PS1 mice (Figure 3C-H). At the cellular level, 
immunoreactivity for GABAB1 was observed in somata of 
CA1 and CA3 pyramidal cells and granule cells in the 
dentate gyrus, as well as in somata of  some interneurons 
scattered throughout the hippocampus (Figure 3C-H). The 
accumulation of  Aβ was very high throughout the hip-
pocampus and particularly high in the stratum lacunosum-
moleculare of  the CA1 region and all layers of  the dentate 
gyrus compared to age-matched wild-type mice (Figure 3I,J). 
Regardless of  this massive accumulation of  Aβ, the cel-
lular distributions for GABAB1 were very similar in wild 
type compared to APP/PS1 mice.
Altered distribution of GABAB1 at the plasma 
membrane of 6 months old APP/PS1 mice
To explore how GABAB receptors are organized along the 
plasma membrane of pyramidal cells, as well as their pos-
sible alteration in the hippocampus of APP/PS1 mice, the 
subcellular localization of the receptors was investigated in 
the CA1 region of hippocampal sections obtained from 1, 
6 and 12  months of age wild-type and APP/PS1 mice. We 
performed highly-sensitive SDS-FRL labeling for GABAB1 
(33) to accurately visualize the two-dimensional distribution 
and precisely calculate the membrane surface densities of 
this subunit. Consistent with previous pre-embedding immu-
nogold labelling studies (27, 32), GABAB1 was detected at 
high densities on the postsynaptic membrane of the entire 
somato-dendritic compartment of CA1 principal cells 
(Figures ‒7).
We initially performed the ultrastructural analysis at 
1  month of age (Figure 4A-G), when no sign of pathology 
is observed in the hippocampus of APP/PS1 mice. Both in 
wild-type and APP/PS1 mice, immunoparticles for GABAB1 
were detected in dendritic spines, dendritic shafts and somata 
(Figure 4A-I). In all neuronal compartments of CA1 pyrami-
dal cells, immunoparticles for GABAB1 were mostly found 
forming clusters, defined as an aggregation of more than 
three gold particles and less frequently scattered or isolated 
single gold particle (Figure 4A-I). The subcellular distribu-
tion pattern and intensity of GABAB1 labeling observed in 
wild type at 1  month of age (Figure 4A-E) was similar to 
that found in APP/PS1 at the same age (Figure 4F-I). Virtually 
no labeling was observed on the E-face or on cross-fractures 
(Figure 4A-I). Next, we performed a quantitative comparison 
of the GABAB1 densities in 11 different somato-dendritic 
compartments in the CA1 region (Figure 4J). Our data 
revealed a similar graded increase in the density of GABAB1 
immunoparticles from the soma to the dendritic spines, but 
more importantly demonstrated similar GABAB1 densities 
along CA1 pyramidal cells in wild-type and APP/PS1 mice 
(Figure 4J). Altogether, our data show that the membrane 
surface localization of GABAB1 did not change in 1  month 
old APP/PS1 mice compared to wild type controls.
Next, we performed the ultrastructural analysis at 
6  months of  age (Figure 5A-H), when Aβ deposition in 
APP/PS1 mice is accumulating in the hippocampus. In 
wild-type and APP/PS1 mice, immunoparticles for GABAB1 
were detected in dendritic spines, dendritic shafts and 
somata, most frequently forming clusters and less frequently 
showing a scattered isolated distribution (Figure 5A-H). 
The subcellular distribution of  GABAB1 immunogold labe-
ling observed at 6  months of  age was similar in wild-type 
and APP/PS1 mice (Figure 5A-H). Virtually no labeling 
was observed on the E-faces or on cross-fractures (Figure 
5A-H). Quantitative comparison of  the GABAB1 densities 
along the membrane surface of  CA1 pyramidal neurons 
revealed two main findings: 1) a graded increase in the 
density of  GABAB1 immunoparticles from the soma to 
the dendritic spines, and 2) similar GABAB1 densities along 
CA1 pyramidal cells in wild-type and APP/PS1 mice, with 
exception of  the stratum lacunosum-moleculare, where the 
GABAB1 density varied substantially between wild-type 
and APP/PS1 mice (Figure 5I). Indeed, our analysis dem-
onstrated the labeling intensity was significantly reduced 
Figure 2. Hippocampal expression and distribution of GABAB1 in wild-
type and APP/PS1 mice. A-I. The expression of the GABAB1 protein was 
visualized in histoblots of horizontal brain sections at 1, 6 and 12 months 
of age in wild-type and APP/PS1 mice using an affinity-purified anti-
GABAB1 antibody. GABAB1 expression in different hippocampal subfields 
and dendritic layers was determined by densitometric analysis of the 
scanned histoblots. GABAB1 expression was moderate to strong in all 
dendritic layers of the CA1 and CA3 region and dentate gyrus, with the 
stratum lacunosum-moleculare (slm) of CA3 showing the highest 
expression level. Densitometric analysis showed no differences in 
GABAB1 expression in APP/PS1 mice compared to age-matched wild 
type controls. J,K. Western blots showing the expression of the GABAB1 
protein in the hippocampus at 1, 6 and 12 months of age in wild-type 
and APP/PS1 mice. Crude membrane preparations were subjected to 
7.5% SDS-PAGE, transferred on to polyvinylidene difluoride membranes. 
They were reacted with an anti-pan GABAB1 antibody, which recognised 
both GABAB1a and GABAB1b subunits with estimated molecular masses 
of 130 and 100  kDa, respectively. The developed immunoblots were 
scanned and densitometric measurements from five independent 
experiments were averaged together to compare the protein densities 
for each age and experimental group. Quantification of GABAB1a and 
GABAB1b normalised to α-tubulin and expressed as pixel density showed 
no differences in APP/PS1 mice compared to age-matched wild type 
controls. Error bars indicate SEM. L,M. Characterization of the 
monoclonal anti-GABAB1 in the mouse brain. The pattern of GABAB1 
expression observed in the wild type using histoblot disappeared 
completely in the brain of GABAB1 null mice (GABAB1-/-). Using western 
blots, immunolabeling signal was abolished in the GABAB1-/- mice, while 
strong bands for GABAB1a and GABAB1b subunits were present in the 
wild type. Scale bars: A,B,D,E,G,H, 0.05  cm; L, 0.5  cm. [Correction 
added on 6 March 2020, after first online publication: The western blot 
image in Figure 2 has been amended to a version without splicing.]
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in oblique dendrites (oDen) and spines in APP/PS1 mice 
(oDen = 28.83  ±  3.45 immunoparticles/μm2, n = 16 den-
drites; s = 49.76 ± 8.79 immunoparticles/μm2, n = 21 spines) 
compared to age-match wild-type mice (oDen = 64.34 ± 
4.86 immunoparticles/μm2, n = 16 dendrites; s = 101.58 
±  13.93 immunoparticles/μm2, n  =  21 spines) (Two-way 
ANOVA test and Bonferroni post hoc test, *P  <  0.05; 
****P  <  0.0001) (Figure 5I). Altogether, our data at 
6  months of  age shows that the plasma membrane locali-
zation of  GABAB1 in APP/PS1 is selectively altered in 
distal dendrites and spines located in the stratum 
lacunosum-moleculare.
Reduction of GABAB1 in the plasma membrane 
of 12 months old APP/PS1 mice
We further investigated the membrane localization of GABAB 
receptors in APP/PS1 mice at 12  months of age, when Aβ 
deposition is large and cognitive deficits and synapse loss 
are severe (Figure 6A-N). Immunoparticles for GABAB1 were 
detected along the membrane surface of CA1 pyramidal 
cells in dendritic compartments and cell bodies in wild- type 
and APP/PS1 mice (Figure 6A-F). In all strata and neuronal 
compartments of CA1 pyramidal cells, most immunoparticles 
for GABAB1 were found in clusters, with three or more 
particles and less frequently scattered single gold particles 
Figure 3. Regional and cellular distribution of GABAB1 in wild-type and 
APP/PS1 mice. A-H. Immunoreactivity for GABAB1 in the hippocampus 
of wild-type and APP/PS1 mice at 12  months of age using a pre-
embedding immunoperoxidase method at the light microscopic level. In 
the CA1 and CA3 regions and dentate gyrus (DG), GABAB1 
immunoreactivity was very similar both in the wild-type and the APP/
PS1 mice, regardless of accumulation of amyloid plaques (asterisks). 
Labeling for GABAB1 showed the highest intensity in the stratum 
lacunosum-moleculare (slm) and molecular layer (ml) and weaker in the 
strata oriens (so) and radiatum (sr). Immunoreactivity for GABAB1 was 
also detected in interneurons throughout all layers (white arrows), with 
similar distribution pattern and labeling intensity in wild-type and APP/
PS1 mice. I,J. Immunoreactivity for β-amyloid in wild-type and APP/PS1 
mice at 12 months of age, showing high accumulation of Aβ throughout 
all layers of the hippocampus. Abbreviations: CA1 region of the 
hippocampus; CA3, CA3 region of the hippocampus; DG, dentate gyrus; 
so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; slm, 
stratum lacunosum-moleculare; ml, molecular layer; gc, granule cell 
layer; h, hilus. Scale bars: A,B,I,J 200 µm; C-H, 100 µm.
Decrease of GABAB receptors in Alzheimer's diseaseMartín-Belmonte et al
Brain Pathology 30 (2020) 554–575
© 2019 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
563
outside the clusters (Figure 6A-F). No labeling was observed 
on the E-face or on cross-fractures (Figure 6A-F). In APP/
PS1 mice, GABAB1 immunoparticles were observed in all 
strata in the CA1 region, but their distribution pattern 
changed significantly. Thus, both fewer immunoparticles and 
fewer clusters were detected along the membrane surface 
of CA1 pyramidal cells (Figure 6G-N).
Next, we performed a quantitative comparison of the 
GABAB1 densities in somato-dendritic compartments of CA1 
pyramidal cells (Figure 7A). This analysis revealed a sig-
nificant decrease between wild-type and APP/PS1 mice in 
all strata analyzed (Figure 7A). Altogether, our data shows 
that the membrane surface localization of GABAB1 was 
reduced significantly in 12-month-old APP/PS1 mice 
Figure 4. Subcellular localization of GABAB1 in the hippocampus in wild-
type and APP/PS1 mice at 1  month. Electron micrographs obtained 
from different strata of the CA1 region showing immunoparticles for 
GABAB1 along the membrane surface of pyramidal cells, as detected 
using the SDS-FRL technique. A-H. In wild type and APP/PS1, clusters 
of GABAB1 immunoparticles (blue ellipses/circles) associated with the 
P-face were detected in dendritic shafts, illustrated here for oblique 
dendrites (oDen) and dendritic spines (s) of pyramidal cells in all strata 
of the CA1 region. Lower density of immunoparticles for GABAB1 was 
also detected scattered (purple arrows) outside the clusters. Fractured 
spine necks are indicated with asterisks (*). The E-face is free of any 
immunolabeling. J. Quantitative analysis of GABAB1 immunogold 
labeling in eleven neuronal compartments. The density gradient of 
GABAB1 immunoparticles along the membrane surface of CA1 pyramidal 
cells was very similar between wild-type and APP/PS1 mice. Error bars 
indicate SEM. Abbreviations: so, stratum oriens; sp, stratum pyramidale; 
sr, stratum radiatum; slm, stratum lacunosum-moleculare; aDen, apical 
dendrite; oDen, oblique dendrite; s, spine; SM, soma. Scale bars: A,C,D, 
0.5 μm; B,E-I, 0.2 μm. 
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(Two-way ANOVA test and Bonferroni post hoc test, 
*P  <  0.05; ****P  <  0.0001).
Finally, to determine how the reduction in GABAB1 
density is taking place at the membrane surface of  CA1 
pyramidal cells in 12-month-old APP/PS1 mice, we ana-
lyzed the composition of  clusters of  GABAB1 
immunoparticles in dendritic shafts and spines along the 
membrane surface in the different hippocampal layers. We 
analyzed neuronal compartments in all strata, but provide 
only the example of  oDen in the proximal and distal 
parts of  the stratum radiatum and the stratum lacunosum-
moleculare (Figure 7B). To avoid differences in the size 
Figure 5. Subcellular localization of GABAB1 in the hippocampus in wild-
type and APP/PS1 mice at 6  months. Electron micrographs obtained 
from different strata of the CA1 region showing immunoparticles for 
GABAB1 along the membrane surface of pyramidal cells, as detected 
using the SDS-FRL technique. A-H. In wild type and APP/PS1, clusters 
of GABAB1 immunoparticles (blue ellipses/circles) associated with the 
P-face were detected in dendritic shafts, illustrated here for oblique 
dendrites (oDen) and dendritic spines (s) of pyramidal cells in all strata 
of the CA1 region. Lower density of immunoparticles for GABAB1 was 
also detected scattered (purple arrows) outside the clusters. Fractured 
spine necks and other cross-fractures are indicated with asterisks (*). 
The E-face is free of any immunolabeling. I. Quantitative analysis of 
GABAB1 immunogold labeling in 11 neuronal compartments of CA1 
pyramidal cells. The density gradient of membrane surface GABAB1 
immunoparticles was very similar between wild-type and APP/PS1 mice 
in all strata except in the stratum lacunosum-moleculare (slm), where 
we found significant differences in both oblique dendrites (WT: 
60.27  ±  5.60 immunoparticles/µm2; APP/PS1: 35.37  ±  3.61 
immunoparticles/µm2) and dendritic spines (WT: 103.68  ±  18.69 
immunoparticles/µm2; APP/PS1: 58.09  ±  13.78 immunoparticles/µm2) 
(Two-way ANOVA test and Bonferroni post hoc test, *P  <  0.05; 
****P < 0.0001). Error bars indicate SEM. Abbreviations: so, stratum 
oriens; sp, stratum pyramidale; sr, stratum radiatum; slm, stratum 
lacunosum-moleculare; aDen, apical dendrite; oDen, oblique dendrite; s, 
spine; SM, soma. Scale bars: A,G, 0.25  μm; B-F,H, 0.5  μm. 
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Figure 6. The density of plasma membrane of GABAB1 is reduced in the 
hippocampus of APP/PS1 mice at 12 months. Electron micrographs of 
the CA1 region showing immunoparticles for GABAB1 along the 
membrane surface of pyramidal cells, as detected using the SDS-FRL 
technique. A-F. In wild type, clusters of GABAB1 immunoparticles (blue 
ellipses/circles) associated with the P-face were detected in dendritic 
shafts, illustrated here for oblique dendrites (oDen) and dendritic spines 
(s) of pyramidal cells in all strata of the CA1 region. Lower density of 
immunoparticles for GABAB1 was also detected scattered (purple 
arrows) outside the clusters. G-N. In APP/PS1, surface GABAB1 
immunoparticles were detected in the P-face of all compartments of 
CA1 pyramidal cells. However, GABAB1 immunoparticles were detected 
at lower frequency forming clusters (blue ellipses/circles), being 
showing a scattered distribution (purple arrows). Fractured spine necks 
and other cross-fractures are indicated with asterisks (*). The E-face is 
free of any immunolabeling. Scale bars: A-N, 0.2 μm. 
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of  dendrites present in each EM picture analyzed or den-
dritic alterations induced by AD, we performed this analysis 
in a similar total area (140.00 µm2) of  oDen. In the 
proximal part of  the stratum radiatum, we detected a total 
of  68 clusters with a range of  3 to 12 immunoparticles 
in APP/PS1 mice, while detected 298 clusters with a range 
of  3 to 29 immunoparticles for GABAB1 in wild-type mice 
(Figure 7B). In the distal part of  the stratum radiatum, 
we detected a total of  57 clusters with a range of  3 to 
12 immunoparticles in APP/PS1 mice, while detected 204 
clusters with a range of  3 to 29 immunoparticles for 
GABAB1 in wild-type mice (Figure 7B). Similarly, in the 
stratum lacunosum-moleculare, we detected a total of  60 
clusters with a range of  3 to 13 immunoparticles in APP/
PS1 mice, while we detected 234 clusters with a range of 
3 to 37 immunoparticles for GABAB1 in wild-type mice 
(Figure 7B). Altogether, the analysis showed that the 
number and the size of  clusters of  GABAB1 immunopar-
ticles were reduced in the two dendritic layers in the APP/
PS1 mice.
Reduction in the density of presynaptic GABAB1 
in 12-month-old APP/PS1 mice
Immunoparticles for GABAB1 were not only confined to 
somato-dendritic domains of CA1 pyramidal cells, but also 
present in axon terminals, as previously reported (27, 32). 
Thus, we further investigated whether the localization of 
GABAB1 at presynaptic sites is altered in the hippocampus 
of APP/PS1 (Figure 8), paralleled to the decrease found in 
somato-dendritic compartments at 12  months of age. We 
performed SDS-FRL labeling for GABAB1 to unravel its 
membrane surface densities in the strata radiatum and 
lacunosum-moleculare of  the CA1 region. In wild-type 
Figure 7. Density gradient of GABAB1 immunoparticles along the 
membrane surface of CA1 pyramidal cells in wild type and APP/PS1 
mice at 12  months. A. Quantitative analysis of GABAB1 immunogold 
labeling in eleven neuronal compartments of CA1 pyramidal cells. The 
density gradient of membrane surface GABAB1 immunoparticles was 
significantly reduced in the APP/PS1 mice compared to age-matched 
wild type controls in all strata and compartments analyzed Two-way 
ANOVA test and Bonferroni post hoc test, *P < 0.05; ****P < 0.0001). 
Error bars indicate SEM. Abbreviations: so, stratum oriens; sp, stratum 
pyramidale; sr, stratum radiatum; slm, stratum lacunosum-moleculare; 
aDen, apical dendrite; oDen, oblique dendrite; s, spine; SM, soma. 
B. Quantitative analysis showing composition of clusters of GABAB1 
immunoparticles along the membrane surface in the strata radiatum 
and lacunosum-moleculare in wild-type and APP/PS1 mice at 12 months 
on age in oblique dendrites. In the two dendritic layers analyzed, the 
number and size of clusters of GABAB1 immunoparticles was reduced in 
the APP/PS1 mice (68 clusters with a range of 3 to 12 immunoparticles 
in the sr; 60 clusters with a range of 3 to 13 immunoparticles in the slm) 
compared to age-matched wild type controls (298 clusters with a range 
of 3 to 21 immunoparticles in the sr; 230 clusters with a range of 3 to 22 
immunoparticles in the slm).
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animals, immunoparticles for GABAB1 were detected within 
the active zone of axon terminals, identified by the concave 
shape of the P-face and the accumulation of IMPs (23) 
and along the extrasynaptic site of axon terminals (Figure 
8A-C). GABAB1 immunoparticles were detected both form-
ing clusters and scattered outside the clusters, both in the 
active zone and at the extrasynaptic sites (Figure 8A-C). 
The density of GABAB1 immunoparticles was higher at the 
active zones (AZ; sr  =  103.31  ±  20.16 immunoparticles/
µm2, n  =  82 particles; slm  =  109.03  ±  21.62 immunopar-
ticles/µm2, n  =  149 particles) than at the extrasynaptic sites 
(Extra; sr  =  42.97  ±  4.47 immunoparticles/µm2, n  =  305 
particles; slm  =  60.79  ±  6.11 immunoparticles/µm2, n  =  347 
particles) (Figure 8F). In APP/PS1 animals, GABAB1 immu-
noparticles were detected in the same presynaptic compart-
ments also showing larger density at the active zone terminals 
than at extrasynaptic sites, showing clusters and scattered 
distributions (Figure 8D-E). However, quantitative compari-
sons with age-matched wild-type mice did not show differ-
ences in the density of GABAB1 immunoparticles in the sr 
(AZ = 120.95 ± 24.58 immunoparticles/µm2, n = 79 particles; 
Extra = 28.08 ± 4.96 immunoparticles/µm2, n = 81 particles) 
(Two-way ANOVA test and Bonferroni post hoc test, 
p  =  0.68), while we found significant differences in the slm 
(AZ  =  17.32  ±  4.99 immunoparticles/µm2, n  =  19 particles; 
Extra = 24.64 ± 5.17 immunoparticles/µm2, n = 67 particles) 
(Two-way ANOVA test and Bonferroni post hoc test, 
*P  <  0.05) (Figure 8F).
To test the consistency and  specificity on  the reduction 
of  GABAB receptors in the APP/PS1 mice described above, 
as control of  our technical approach and mouse model 
we analysed the distribution of  four different proteins: 
Figure 8. Presynaptic localization of GABAB1 in the hippocampus in 
wild-type and APP/PS1 mice. Electron micrographs showing 
immunoparticles for GABAB1 in presynaptic compartments in the strata 
radiatum (sr) and lacunosum-moleculare (slm) of the CA1 region of the 
hippocampus at 12  months of age, as detected using the SDS-FRL 
technique. A-C. In wild type, immunoparticles for GABAB1 were found 
within the active zone (az, purple overlay), recognized by the concave 
shape of the P-face and the accumulation of IMPs, and along the 
extrasynaptic site of axon terminals (ax), forming clusters (blue ellipses/
circles) and also detected scattered (purple arrows) outside the clusters. 
D,E. In APP/PS1, fewer immunoparticles for GABAB1, forming clusters 
(blue ellipses/circles) or scattered (purple arrows), were detected within 
the active zone (az, purple overlay) and along the extrasynaptic plasma 
membrane of axon terminals (ax). Cross-fractures are indicated with 
asterisks (*). F. Densities of immunoparticles for GABAB1 in presynaptic 
compartments in the sr and slm in wild-type and APP/PS1 mice. No 
differences were detected in densities of GABAB1 immunoparticles in 
the sr (WT: AZ  =  103.31  ±  20.16 immunoparticles/µm2 and 
Extra = 42.97 ± 4.47 immunoparticles/µm2; APP: AZ = 120.95 ± 24.58 
immunoparticles/µm2; Extra = 28.08 ± 4.96 immunoparticles/µm2), but 
significant differences were detected in the slm (WT: AZ = 109.03 ± 21.62 
immunoparticles/µm2 and Extra = 60.79 ± 6.11 immunoparticles/µm2; 
APP: AZ  =  17.32  ±  4.99 immunoparticles/µm2; Extra  =  24.64  ±  5.17 
immunoparticles/µm2) (Two-way ANOVA test and Bonferroni post hoc 
test, *P < 0.05). Error bars indicate SEM. Scale bars: A-E, 0.2 μm. 
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(i) AMPA receptors, known to localise in excitatory syn-
apses in an activity-dependent manner (Supplementary 
Figure S1); (ii) the GluN1 subunit of  NMDA receptors, 
which are not incorporated in an activity-dependent man-
ner into synapses (Supplementary Figure S2); (iii) the 
GIRK2 subunit of  G protein-gated inwardly rectifying 
potassium channels, which are known effector ion chan-
nels of  GABAB receptors (Supplementary Figure S2); and 
(iv) the synaptosomal-associated protein SNAP-25, which 
is responsible for the Ca2+-dependent exocytosis of  neu-
rotransmitters, thus playing a key role to normal function-
ing of  brain (Supplementary Figure S2). Thus, using the 
SDS-FRL method, we determined the densities of  the 
four proteins receptors at synapses of  the stratum lacu-
nosum-moleculare (the subfield in which we detected most 
alteration in the localization of  GABAB receptors) in the 
CA1 region of  hippocampal sections. In APP/PS1 mice, 
compared to control mice, lower density of  immunopar-
ticles for AMPA (Supplementary Figure S1) and NMDA 
(Supplementary Figure S2) were detected in excitatory 
synapses of  dendritic spines, fewer immunoparticles for 
GIRK2 (Supplementary Figure S2) were detected in den-
dritic shafts and spines of  pyramidal cells and fewer 
immunoparticles for SNAP-25 (Supplementary Figure S2) 
were detected in axon terminals establishing excitatory 
synapses with dendritic spines. These reductions, which 
are in agreement with the current literature, validate the 
effect described for GABAB receptors.
Increase of GABAB1 in the cytoplasm of CA1 
pyramidal cells and axon terminals in APP/PS1 
mice
We next sought to investigate why the localization of 
GABAB1 in the membrane surface of  CA1 pyramidal cells 
and axon terminals is significantly reduced in the hip-
pocampus of  APP/PS1 at 12  months of  age when the 
total amount of  protein remains invariable, as shown by 
histoblots and western blots. To explore possible receptor 
internalization and accumulation in intracellular domains 
of  CA1 pyramidal cells and axon terminals of  APP/PS1 
mice compared to age-matched wild type controls, the 
subcellular localization of  GABAB1 was investigated at 1, 
6 and 12  months of  age. We used the pre-embedding 
immunogold technique and quantitative analysis on tissue 
blocks taken from the proximal part of  the stratum radia-
tum and the stratum lacunosum-moleculare of  the CA1 
area.
At 1  month of  age, immunoreactivity for GABAB1 was 
primarily found along the extrasynaptic plasma membrane 
of  dendritic spines and shafts of  CA1 pyramidal cells 
and also associated at intracellular sites in dendritic spines 
(Figure 9A,B). Quantitative analysis performed in the strata 
radiatum (sr) and lacunosum-moleculare (slm) of  the CA1 
area showed similar proportion of  postsynaptic GABAB1 
immunoparticles in the plasma membrane vs. intracellular 
in APP/PS1 (Plasma membrane: 65.52% in sr and 65.11% 
in slm; Intracellular: 34.48% in sr and 34.89% in slm) 
and age-matched wild-type mice (Plasma membrane: 64.04% 
in sr and 64.68% in slm; Intracellular: 35.96% in sr and 
35.32% in slm) (Figure 9C).
At 6  months of age, immunoreactivity for GABAB1 fol-
lowed similar distribution than at 1  month, being also 
observed along the extrasynaptic plasma membrane and 
intracellular sites of dendritic spines and shafts of CA1 
pyramidal cells (Figure 9D-E). However, quantitative analysis 
showed some differences in the plasma membrane vs. intra-
cellular between the stratum radiatum and the stratum 
lacunosum-moleculare of  the CA1 area. Thus, in the stratum 
radiatum we did not detect differences in the total amount 
of postsynaptic immunoparticles between wild-type and APP/
PS1 mice (Plasma membrane: 63.45% in wild type and 
63.46% in APP/PS1; Intracellular: 36.55% in wild type and 
36.54% in APP/PS1) (Figure 9F). Consistent with this data, 
similar percentage of immunoparticles were observed in 
dendritic spines and shafts between wild-type and APP/PS1 
mice (Figure 9F). However, we detected changes in the 
stratum lacunosum-moleculare in the plasma membrane vs. 
intracellular among wild-type and APP/PS1 mice (Plasma 
membrane: 62.06% in wild type and 41.05% in APP/PS1; 
Intracellular: 37.94% in wild type and 58.05% in APP/PS1) 
(Figure 9F).
At 12  months of  age, immunoreactivity for GABAB1 
was again localized along the extrasynaptic plasma mem-
brane of  dendritic spines and shafts, as well as associated 
at intracellular sites in dendritic spines (Figure 9G-I). 
Quantitative analysis showed clear differences in the plasma 
membrane vs. intracellular both in the stratum radiatum 
(Plasma membrane: 58.81% in wild type and 32.60% in 
APP/PS1; Intracellular: 41.19% in wild type and 67.40% 
in APP/PS1) and the stratum lacunosum-moleculare (Plasma 
membrane: 54.23% in wild type and 15.19% in APP/PS1; 
Intracellular: 45.77% in wild type and 84.81% in APP/
PS1) of  the CA1 area. These differences in plasma mem-
brane vs. intracellular were detected in dendritic shafts 
and spines in the two strata (Figure 9G-I). To clarify the 
intracellular compartments on which GABAB1 is accumu-
lated, we performed double labeling immunofluorescence 
with different markers (Rab4, EEA1, LAMP1 or CHOP). 
We found no differences in the co-localization pattern in 
the APP/PS1 mice compared to age-matched wild type 
controls with the makers employed (Supplementary 
Figure S4).
Presynaptically, immunoreactivity for GABAB1 was occa-
sionally detected in axon terminals establishing asymmetrical 
synapses with dendritic spines (Figure 9). At 1  month of 
age, GABAB1 presynaptic labeling was similar between wild-
type and APP/PS1 animals (Figure 9C). At 6  months of 
age, we detected changes in the plasma membrane vs. intra-
cellular among wild type and APP/PS1 in the stratum radiatum 
(Plasma membrane: 57.57% in wild type and 46.30% in APP/
PS1; Intracellular: 42.42% in wild type and 53.70% in APP/
PS1) and stratum lacunosum-moleculare (Plasma membrane: 
62.12% in wild type and 39.25% in APP/PS1; Intracellular: 
37.88% in wild type and 60.75% in APP/PS1) (Figure 9F). 
These differences were more pronounced at 12  months of 
age, detecting changes in the stratum radiatum (Plasma mem-
brane: 60.78% in wild type and 33.33% in APP/PS1; 
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Intracellular: 39.22% in wild type and 66.67% in APP/PS1) 
and stratum lacunosum-moleculare (Plasma membrane: 65.22% 
in wild type and 31.25% in APP/PS1; Intracellular: 34.78% 
in wild type and 68.75% in APP/PS1) (Figure 9I).
Finally, to validate the described reduction of post and 
presynaptic GABAB receptors in the hippocampus of APP/
PS1 mice, we determined their expression levels together 
with other markers in human tissue. Thus, using 
Figure 9. Intracellular distribution of GABAB1 is increased in the 
hippocampus of APP/PS1 mice. Electron micrographs showing 
immunoparticles for GABAB1 in pyramidal cells of the CA1 region at 1, 6 
and 12  months of age in wild -type and APP/PS1 mice, as detected 
using a pre-embedding immunogold technique and obtained from the 
stratum lacunosum-moleculare for illustrative purposes. A,B,D,E,G,H. 
In all those animals and ages, GABAB1 immunoparticles were found 
along the extrasynaptic plasma membrane (arrows) and intracellular 
sites (crossed arrows) of dendritic shafts (Den) and spines (s) of CA1 
pyramidal cells contacted by axon terminals (at), and less frequently at 
presynaptic sites (arrowheads). C. Quantitative analysis at 1 month in 
the strata radiatum and lacunosum-moleculare showed that the 
proportion of postsynaptic GABAB1 immunoparticles along the plasma 
membrane (65.52% in sr and 65.11% in slm) and intracellular sites 
(34.48% in sr and 34.89% in slm) in APP/PS1 was similar to age-
matched wild-type mice (Plasma membrane: 64.04% in sr and 64.68% 
in slm; Intracellular: 35.96% in sr and 35.32% in slm) in dendritic spines 
and shafts of CA1 pyramidal cells. F. Quantitative analysis at 6 months 
showed no changes in the stratum radiatum (Plasma membrane: 
63.45% in wild type and 63.46% in APP/PS1; Intracellular: 36.55% in 
wild type and 36.54% in APP/PS1), but a clear reduction of plasma 
membrane GABAB1 at postsynaptic compartments, with a subsequent 
increase in cytoplasmic sites, in APP/PS1 mice (Plasma membrane: 
62.06% in wild type and 41.05% in APP/PS1; Intracellular: 37.94% in 
wild type and 58.05% in APP/PS1). (I) Quantitative analysis at 12 months 
of age showing that GABAB1 immunoparticles were less frequently 
observed along the extrasynaptic plasma membrane dendrites and 
spines of CA1 pyramidal cells in APP/PS1 mice, as well at presynaptic 
sites, but instead they more frequently detected at intracellular sites in 
both the strata radiatum (Plasma membrane: 58.81% in wild type and 
32.60% in APP/PS1; Intracellular: 41.19% in wild type and 67.40% in 
APP/PS1), proximal and distal parts, and lacunosum-moleculare (Plasma 
membrane: 54.23% in wild type and 15.19% in APP/PS1; Intracellular: 
45.77% in wild type and 84.81% in APP/PS1). Scale bars: A,B,D,E, 
1 μm; G,H, 0.5 μm. 
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immunoblots we assessed the expression levels of GABAB1, 
GluA1, GluA2 and GluN1 in tissue lysates of the hip-
pocampus in control and AD cases (Supplementary Figure 
S3A). Quantification of all these immunoreactive bands 
revealed that GABAB1, GluA1, GluA2 and GluN1 proteins 
were significantly reduced in the hippocampus of AD sub-
jects compared to controls (Supplementary Figure S3B).
DISCUSSION
To understand the mechanisms that are operative in AD, 
it is important to appreciate that alteration of neurotrans-
mitter receptors must be a common denominator of dendritic 
spines loss and synaptic impairment, two critical events in 
the pathophysiology of this neurodegenerative disease (42, 
48, 54). We hypothesize that neurons experiencing AD neu-
ropathology may selectively regulate neurotransmitter recep-
tors associated with excitatory synapses, thus contributing 
to neuronal damage and to the cognitive decline associated 
with AD. However, the receptors and ion channels involved 
in the synaptic deficits present in pathological conditions 
are still poorly known. Identification of the molecular mecha-
nisms at central synapses affected by AD may allow devel-
oping more effective therapeutic approaches for AD, for 
which no curative treatment is yet available. Here, we have 
demonstrated for the first time a compartment- and age-
dependent reduction of surface GABAB receptors and a 
parallel intracellular increase of these receptors in CA1 
pyramidal cells with progressive neuropathology in an AD 
mouse model, the APP/PS1 model. We additionally show 
that the decrease of GABAB receptors also affects in an 
age-dependent manner axon terminals contacting CA1 
pyramidal cells. The significant reduction in GABAB recep-
tors may contribute to the pathology and memory impair-
ment associated with AD.
Unchanged expression of hippocampal GABAB 
receptor protein in Alzheimer's disease
Dysfunction of the hippocampus largely contributes to the 
memory deficits that characterise AD  (31, 44). In contrast 
to the large interest focused on the potential role of glu-
tamate receptors in AD (11, 39), less information is available 
about the involvement of GABA receptors. In particular, 
GABAB receptors also play a role in learning and memory 
(19). Recent studies reported that GABAB receptors selec-
tively co-purify with APP (47) and this macromolecular 
complex links presynaptic GABAB receptor trafficking to 
Aβ formation (9). In addition, GABAB1a has been identified 
as a receptor for secreted APP, which would regulate the 
function of the receptor isoform to modulate synaptic trans-
mission and plasticity (45). For these reasons, our work 
adopted transgenic mice overexpressing mutant familial AD 
genes [amyloid-β protein precursor (AβPP), presenilin-1 (PS1), 
and PS2], considered one of the most relevant animal models 
of AD. These animals show Aβ deposition by 4  months 
with a progressive increase in senile plaque number up to 
12  months and cognitive impairments (14, 15).
In the present study, we demonstrated with different 
approaches that total protein levels of GABAB receptors 
were not significantly changed in APP/PS1 mice with the 
progressive increase of Aβ levels at different ages in the 
hippocampus. This does not seems to be the case for other 
components of the GABA receptor systems, as GABAA 
receptors are differentially affected in AD in a region- and 
subunit-dependent manner. Thus, some GABAA subunits 
showed decrease expression in the human hippocampus, 
although some others remain unchanged (28). In contrast, 
our data also show reduction of GABAB1 protein level in 
the hippocampus of AD patients, consistent with the reported 
downregulation in the gene expression of GABAB1 in AD 
(43). This discrepancy could be due to posttranscriptional 
changes in the control of gene expression at the RNA level, 
but more likely could be the result of differences in brain 
organisation between humans and mice, because the APP/
PS1 model does not develop neurofibrillary tangles, other 
typical pathologic alterations observed in AD human patients, 
or because the stages of AD in the patients were more 
severe than the AD neuropathology suffered by mice at 
12  months of age.
Ultrastructural studies in the hippocampus have shown 
that GABAB receptors are enriched in the vicinity of 
excitatory synapses, supporting the idea that glutamate 
receptors can influence GABAB receptor signaling (27, 32, 
53). Indeed, NMDA receptor activation can induce phos-
phorylation on the GABAB1 and GABAB2 subunits to 
promote endocytosis (17, 51). GABAB receptors can also 
influence the NMDA-mediated excitatory postsynaptic 
potentials in the CA1 region of  the hippocampus (38). 
An autoradiography study of  GABAB receptor expression 
in the human hippocampus of  AD patients indicated fewer 
GABAB receptors in the molecular layer of  the dentate 
gyrus, and the strata pyramidale and lacunosum-moleculare 
of  the CA1 region (7). Our current knowledge of  the 
complexity of  receptor organization in central neurons 
demands more exacting techniques that allow precise iden-
tification and localization of  individual receptor subtypes 
to unravel their distribution in AD. Thus, the SDS-FRL 
and pre-embedding immunogold techniques were the meth-
ods of  choice to decipher the density of  GABAB1 in hip-
pocampal neurons.
Plasma membrane reduction of GABAB 
receptors in the hippocampus of Alzheimer's 
disease
One of  the major research aims in this work has been 
to examine the possibility that, despite the unchanged 
protein levels in the APP/PS1 model of  AD, GABAB 
receptors may still undergo changes in their localization 
along the plasma membrane vs. cytoplasmic sites with 
pathology progression. For that purpose we concentrated 
in the CA1 region of  the hippocampus using the SDS-
FRL technology, proved to be an excellent tool to study 
the high-resolution subcellular localization of  surface-
localized proteins (50). Using this technique, we were able 
Decrease of GABAB receptors in Alzheimer's diseaseMartín-Belmonte et al
Brain Pathology 30 (2020) 554–575
© 2019 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
571
to fully map the two-dimensional distribution of  GABAB 
receptors obtaining very accurate data about their density 
in different compartments of  CA1 pyramidal cells in brains 
displaying AD pathology at a level of  detail never previ-
ously attained.
Our analysis revealing that GABAB receptors are dif-
ferentially localized to somato-dendritic compartments of 
hippocampal principal cells, both in wild type and APP/
PS1 at the three ages studied is in line with results of 
previous immunoEM investigations performed in young 
adult animals (12, 27, 32, 53). More importantly, the 
principal and exciting finding from our results is the reduc-
tion in the density of  plasma membrane-targeted GABAB 
receptors in an age- and compartment-dependent manner. 
Thus, we detected significant differences in the plasma 
membrane distribution of  GABAB1 and subsequent increase 
at cytoplasmic sites only in the stratum lacunosum-molec-
ulare, but found no evidence for changes in all other 
pyramidal cell compartments, at 6  months of  age. This 
observation is consistent with the evidence that density 
of  binding sites for GABAB receptors are decreased in 
stratum lacunosum-moleculare of  the CA1 region in human 
hippocampus with AD (7). Since this hippocampal region 
is the common location for large accumulation of  Aβ in 
AD (22), the decrease in density of  surface GABAB1 in 
the stratum lacunosum-moleculare of  the CA1 region may 
reflect changes due to entorhinal cortical pathology. 
Previous work demonstrated that AD pathology begins 
in the entorhinal cortex and spreads through synaptic 
connections to the hippocampus (31) and the resulting 
hippocampal synaptic weakening induced in the entorhinal 
cortex is a consequence of  the pathologic increase of  Aβ 
and p-tau (49).
At more advanced stages of  AD pathology APP/PS1 
mice show high-density of  Aβ and severe cognitive impair-
ments develop (2, 15). Our analysis performed at 12 months 
of  age revealed a significant reduction in the membrane 
surface distribution of  GABAB1 in all neuronal compart-
ments. The possibility that these immunohistochemical 
findings in APP/PS1 are due to technical issues or storage 
conditions is unlikely because wild-type and APP/PS1 mice 
were always matched from same litters and although dys-
trophic dendrites were observed in these transgenic mice 
(2) our investigation was performed in the Aβ plaque-free 
regions from these animals. Following the finding on the 
reduction of  GABAB1 along the membrane surface of  CA1 
pyramidal cells in APP/PS1 mice, we investigated potential 
internalization at cytoplasmic sites. Immunoelectron micros-
copy and quantitative analysis showed that there is an 
accumulation of  immunoparticles for GABAB1 at cyto-
plasmic sites. Given that the total amount of  GABAB1 
protein does not change between wild-type and APP/PS1 
mice, our data suggests that the internalized pool of 
GABAB receptors was not redirected to subsequent lyso-
somal degradation in AD, in contrast to the activity-
dependent degradation of  GABAB receptors observed in 
hippocampal and cortical neurons (17, 51). Similar plasma 
membrane-cytoplasmic redistribution of  GABAB receptors 
has been reported in GABAergic neurons of  the VTA in 
methamphetamine-injected mice (39).
An additional, interesting finding of  the present study 
is that reduction of  membrane surface GABAB1 in our 
model of  AD was due to alteration in its clustering, with 
lower number of  clusters and fewer immunoparticles per 
cluster. GABAB receptors form macromolecular signaling 
complexes with GIRK channels and Cav channels (40). 
Although no information is yet available about the altera-
tions of  these effector ion channels in AD, the decrease 
of  GABAB receptors from the membrane surface of  CA1 
pyramidal cells, together with the decrease of  GIRK2 
channels we detected in the same compartments, can pro-
duce alteration in GABAB-mediated GIRK currents (39) 
and this could involve a change in G protein-coupling 
efficiency with effector ion channels (29) or simply that 
fewer receptors can couple to channels. Altogether, this 
alteration might be enough to reduce GIRK and/or Cav 
channel conductance in CA1 pyramidal neurons, thus play-
ing a potential role in the hippocampal activity dysfunction 
observed in AD, although this needs to be confirmed 
with electrophysiology.
On the presynaptic side, GABAB receptors mediate slow 
and prolonged synaptic inhibition by activating Cav chan-
nels, thus modulating the release of neurotransmitters (3). 
In the hippocampus, synaptically released GABA can inhibit 
excitatory neurotransmission at the Schaffer collateral syn-
apses in CA1 acting through presynaptic GABAB receptors 
(24). In this study we observed immunoparticles for GABAB1 
along the extrasynaptic membrane and the active zone or 
presynaptic membrane specialization of axon terminals in 
different layers of the CA1 region, in line with previous 
reports using different ultrastructural approaches (27, 53). 
Similarly to the decrease of postsynaptic GABAB receptors, 
we detected a reduction of presynaptic GABAB1 in APP/
PS1 mice of 12  months and this reduction was more pro-
nounced in the stratum lacunosum-moleculare. This data are 
in agreement with a recent study reporting that the increase 
in Aβ production is linked to dysfunctional axonal traffick-
ing and reduced GABAB receptor expression in the APP-/- 
mice (9) and also consistent with the study showing that 
secreted APP binds to GABAB1a (45), an isoform preferentially 
localized at presynaptic sites (53), to supress synaptic vesicle 
release and thus modulating synaptic transmission and plas-
ticity. One way to reduce or supress the release of neuro-
transmitter from synaptic vesicles is by decreasing the number 
of involved receptors in the presynaptic plasma membrane, 
consistent with the reduction of GABAB receptors we have 
reported at presynaptic sites.
CONCLUSIONS
Our work explored the pre and postsynaptic alteration of 
GABAB receptors in hippocampal CA1 pyramidal cells in a 
mouse model of AD, providing new insights into neuro-
transmitter receptor redistribution at different stages of AD 
pathology. This work shows a severe reduction of membrane 
surface GABAB receptors and subsequent accumulation at 
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cytoplasmic sites only at those ages and in those neuronal 
compartments suffering a decrease from the plasma membrane. 
The mechanisms behind these changes in subcellular distribu-
tion and their functional implications are still not known. 
However, the present study and future data in human tissue 
are important to explore how GABAB receptors are involved 
in the altered neuronal excitability associated with AD, essen-
tial information for the development of therapeutic strategies 
for disease improvement. One way of therapeutic intervention 
would be stabilizing of GABAB receptors in the neuronal 
surface, controlled by heteromerization with other proteins, 
and by phosphorylation and dephosphorylation events, and 
regulated by changes in glutamatergic excitatory activity.
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SUPPORTING INFORMATION
Additional supporting information may be found in the online 
version of this article at the publisher’s web site:
Figure S1. Reduced density of synaptic AMPA receptors in 
dendritic spines of APP/PS1 mice at 12 months. (A-F) Electron 
micrographs of  the hippocampus showing immunoparticles 
for pan-AMPA at excitatory synaptic sites of  dendritic spines 
of  pyramidal cells in the CA1 stratum lacunosum-moleculare, 
as detected using the SDS-FRL technique at 1, 6 and 12 
months of  age. Postsynaptic membrane specializations (IMP 
clusters, pseudo coloured in blue for wild type and in red for 
APP/PS1 to aid visualization) show strong immunoreactiv-
ity for pan-AMPA (10 nm gold particles) in the wild type, 
while they show weaker immunoreactivity in the APP/PS1. 
Scale bars: A-F, 200 nm. (G,H,I) Histograms showing the 
distribution of  densities of  gold particles that label AMPA 
receptors in SDS-FRL replicas of  individual postsynaptic 
membrane specializations in wild type and APP/PS1 mice. 
Quantitative analysis showed no changes in the densities of 
AMPA immunoparticles in excitatory synapses in dendritic 
spines at 1 and 6 months of  age (panels G and H). However, 
the analysis showed a significant reduction in the APP/PS1 
mice (205.03 ± 16.88 immunoparticles/µm2) compared to age 
matched wild type (423.20  ±  20.33 immunoparticles/µm2; 
Kruskal–Wallis test, pairwise Mann–Whitney U test and 
Dunn’s method, ***P < 0.001) at 12 months of  age. Error 
bars indicate SEM.
Figure S2. Reduced density of synaptic markers in APP/PS1 
mice at 12 months. (A-F) Electron micrographs of the hippo-
campus showing immunoparticles for the GluN1 subunit of 
the NMDA receptors, the GIRK2 subunit of GIRK chan-
nels and SNP-25 in the CA1 stratum lacunosum-moleculare, 
as detected using the SDS-FRL technique at 12 months of 
age. (A,D) Strong immunoreactivity for GluN1 (10  nm gold 
particles) were observed in postsynaptic membrane special-
izations in the wild type, while weaker immunoreactivity was 
detected in the APP/PS1. (G) Quantitative analysis show-
ing a significant reduction of in the APP/PS1 mice (68.74 ± 
11.15 immunoparticles/µm2) compared to age matched wild 
type (198.56 ± 15.24 immunoparticles/µm2; Kruskal–Wallis 
test, pairwise Mann–Whitney U test and Dunn’s method, 
***p<0.0001). (B,E) Immunoparticles for GIRK2 were 
observed along the surface membrane of dendrites and spines. 
(H) Quantitative analysis showing that immunoreactivity for 
GIRK2 was significantly reduced in oblique dendrites (oDen) 
and spines in APP/PS1 mice (oDen = 92.74 ± 18.12 immuno-
particles/μm2, n = 10 dendrites; s = 128.00 ± 12.38 immuno-
particles/μm2, n = 9 spines) compared to age-match wild type 
mice oDen = 273.10  ±  25.92 immunoparticles/μm2, n  =  10 
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dendrites; s  =  461.92  ±  59.88 immunoparticles/μm2, n  =  10 
spines) (Two-way ANOVA test, *P  <  0.05; ***P  <  0.01). 
(C,F) Immunoreactivity for SNAP-25 were detected along the 
extrasynaptic plasma membrane of axon terminals (at) fac-
ing dendritic spines (s). (I) Our quantitative analysis showed 
a significant reduction in the density of SNAP-25 in the APP/
PS1 mice (30.73 ± 7.58 immunoparticles/µm2) compared to age 
matched wild type (mean  =  134.02  ±  7.46 immunoparticles/
µm2; t test using Holm-Sidak method, ***P  <0.  001). Scale 
bars: A-F, 200 nm. Error bars indicate SEM.
Figure S3. Co-localization of GABAB receptors with 
marker proteins in APP/PS1 mice at 12 months. (A-H) 
Immunofluorescence for GABAB1 (green) and Rab4 (red), 
EEA1 (red), LAMP1 (red) or CHOP (red) in wild type and 
APP/PS1 mice at 12 months of age. The overlay between 
GABAB1 and each marker protein can be seen in yellow (A3-
G3, B3-H3). Co-localization between GABAB1 and the dif-
ferent marker proteins was detected mainly in the somata of 
pyramidal cells in the stratum pyramidale, but no differences in 
the frequency of co-localization was observed in the APP/PS1 
mice compared to age-matched controls. so, stratum oriens; sr, 
stratum radiatum. Scale bars: A-H, 20 µm.
Figure S4. Representative western blots of different molecules 
in the hippocampus from control and Alzheimer´s patients. 
(A) Crude membrane preparations were subjected to 7.5% 
SDS-PAGE, transferred on to polyvinylidene difluoride mem-
branes. They were reacted with an anti-pan GABAB1 antibody, 
which recognised both GABAB1a and GABAB1b subunits with 
estimated molecular masses of 130 and 100 kDa, respectively. 
The antibodies to GluA1, GluA2 detected a single predom-
inant band at 100 kDa and NMDA detected a single pre-
dominant band at 120 kDs. (B) The developed immunoblots 
were scanned and densitometric measurements were averaged 
together to compare the protein densities between controls and 
AD in the hippocampus. Quantification of GABAB1, GluA1, 
GluA2 and GluN1 normalised to α-tubulin and expressed as 
pixel density showed a significant reduction in the amount of 
proteins when compared AD with controls. An antibody anti 
α-Tubulin served as an internal control to ensure comparable 
protein loading showed no significant difference among AD or 
control groups. Data are means ± SEM of represented cases. 
*P  <0. 05; **P < 0.01; ***P < 0.001.
Figure S5. The density of CA1 pyramidal cells is not altered in 
APP/PS1 mice at 12 months. (A) Hippocampal sections from 
WT and APP/PS1 were stained with DAPI. (B) Quantification 
of the number of nuclei in the pyramidal cell layer of the CA1 
region. We confirmed that the number of neurons is similar 
between WT and APP/PS1. Scale bars: A-B, 100 µm.
